Cumulative incidences of acute and chronic GVHD after transplantation and kinetics of immunosuppressant use after transplantation. (A) Cumulative incidence of acute GVHD. The values of grades II to IV acute GVDH on day 100 were 52% (95% CI, 42% to 62%) for CBT and 52% (95% CI, 40% to 64%) for BMT/PBSCT recipients (P = .69). The values of grades III and IV acute GVDH on day 100 were 7% (95% CI, 2% to 13%) for CBT and 19% (95% CI, 19% to 28%) for BMT/PBSCT recipients (P = .04). (B) The cumulative incidence of requiring steroid therapy in patients after cord blood transplantation and bone marrow transplantation/peripheral blood stem-cell transplantation. The values on day 100 were 17% (95% CI, 10% to 24%) for CBT and 38% (95% CI, 27% to 49%) for BMT/PBSCT recipients (P < .01). (C) Cumulative incidence of chronic GVHD in patients surviving more than 100 days. The values for overall chronic GVHD were 71% (95% CI, 62% to 80%) at 1 year and 74% (95% CI, 40% to 64%) at 3 years after cord blood transplantation, in contrast to 68% (95% CI, 56% to 79%) at 1 year and 69% (95% CI, 58% to 80%) at 3 years after bone marrow transplantation/peripheral blood stem-cell transplantation (P = .09). The values of the cumulative incidence of extensive-type GVDH were 22% (95% CI, 14% to 30%) at 1 year and 25% (95% CI, 15% to 32%) at 3 years after cord blood transplantation, in contrast to 44% (95% CI, 32% to 55%) at 1 year and 45% (95% CI, 33% to 57%) at 3 years after bone marrow transplantation/peripheral blood stem-cell transplantation (P = .01).